The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
Home | Video pages | Webcast | CKD-MBD: from bone biopsy to treatment in advanced CKD patients not vice versa